Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 19Myelodysplastic Syndromes 8Congenital Abnormalities 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Mesothelioma, Malignant 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Myelomonocytic, Acute 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Burkitt Lymphoma 3Blast Crisis 3Thrombocythemia, Essential 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Polycythemia Vera 2Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Cisplatin 12Pemetrexed 6Radiotherapy 5Platinum 4Doxorubicin 41,2-diaminocyclohexaneplatinum II citrate 4cediranib 3Mitomycin 3Gemcitabine 3Decitabine 3pembrolizumab 2Vinorelbine 2SS1(dsFv)PE38 2Interferon-gamma 2Gene Expression Profiling 2Erlotinib Hydrochloride 2Depsipeptides 2Cyclophosphamide 2Celecoxib 2sargramostim 1rilotumumab 1ranpirnase 1methoxyamine 1entinostat 1decitabine and cedazuridine drug combination 1cixutumumab 1belinostat 1atezolizumab 1anetumab ravtansine 1alvocidib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Mesothelioma, Malignant × Decitabine × Clear all
NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT00037817 2019-09-30

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
34 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT00019825 2015-04-29

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

National Cancer Institute (NCI)

Phase 1 Completed
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡